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ABSTRACT
Pharmacodynamic exposures, measured as the ratio of steady-state total drug area under the curve to
MIC (AUC ⁄MIC), were modelled using a 5000-patient Monte-Carlo simulation against 119 non-
duplicate clinical isolates of Staphylococcus aureus and 82 coagulase-negative staphylococci (CNS)
collected from hospitals in Brazil between 2003 and 2005. Pharmacodynamic targets included an
AUC ⁄MIC >82.9 for linezolid and >345 for teicoplanin and vancomycin, as well as a free drug
AUC ⁄MIC >180 for vancomycin. The cumulative fractions of response (CFRs) against all S. aureus
isolates were 96.0%, 30.1%, 71.6%, 48.0% and 65.1% for linezolid 600 mg every 12 h, teicoplanin
400 mg every 24 h and 800 mg every 24 h, and vancomycin 1000 mg every 12 h and every 8 h,
respectively. Using a free drug target for vancomycin improved the CFR to 94.6% for the high-dose
regimen, but did not substantially alter results for the lower dose. CFRs against all CNS isolates were
97.8%, 13.4%, 34.6%, 10.9% and 31.3%, respectively, for the same antibiotic regimens. The CFR was
reduced for all compounds among the methicillin-resistant isolates, except for linezolid against
methicillin-resistant CNS. Sensitivity analyses did not alter the final order of pharmacodynamic potency
against these isolates. Although higher doses of vancomycin and teicoplanin increased the CFR, the
likelihood of achieving bactericidal targets was still lower than with linezolid. The results for the high-
dose vancomycin regimen were highly dependent on the pharmacodynamic target utilised. These data
suggest that linezolid has a greater probability of attaining its requisite pharmacodynamic target than
teicoplanin and vancomycin against these staphylococci.
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INTRODUCTION
Although the MIC is an important indicator of the
emerging resistance and decreasing potency of an
antibiotic, it is a relatively imprecise index for the
prediction of clinical outcomes because of the
failure to take into account the pharmacokinetic
profile of the antibiotic and its pharmacodynamic
killing characteristics [1]. The association of MIC
distribution and pharmacokinetic data derived
from microbiological and human studies through
the use of pharmacodynamic models offers a
more sophisticated tool for prediction of the
outcome of infection [2]. The use of Monte-Carlo
simulation, a stochastic prediction tool, provides
an estimate of an antibiotic dosing regimen’s
probability of achieving the targeted pharmaco-
dynamic exposure, given uncertainty in patient
pharmacokinetics and the MIC distribution of the
bacterial population [3].
Pharmacodynamic studies employing Monte-
Carlo simulation are available for comparing the
activity of numerous b-lactam and fluoroquino-
lone antibiotics against both Gram-positive and
Gram-negative bacteria [4,5]. However, this level
of analysis has not yet been applied to reference
standard antibiotics for methicillin-resistant
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staphylococcal infections, e.g., vancomycin and
teicoplanin. Recent studies in patients with seri-
ous infections caused by methicillin-resistant
Staphylococcus aureus (MRSA) suggest that vanco-
mycin may not be an optimal choice because of
increasing MICs [6–8]. However, an exploration
into the exposures achieved at these MIC values
with current vancomycin doses has not been
conducted. It is plausible that increases in the
vancomycin MIC, although remaining within the
range defined as susceptible, no longer allow
the required pharmacodynamic exposure neces-
sary to achieve a bactericidal effect. Accordingly,
the objective of the current study was to deter-
mine the probability of attaining targeted phar-
macodynamic exposure for various regimens of
vancomycin, teicoplanin and the oxazolidinone,
linezolid, against S. aureus and coagulase-nega-
tive staphylococci (CNS) isolates from hospitals
in Sa˜o Paulo, Brazil.
MATERIALS AND METHODS
Microbiology
In total, 201 non-duplicate clinical isolates of S. aureus and
CNS were collected from three hospitals in Sa˜o Paulo, Brazil,
between 2003 and 2005. Linezolid, teicoplanin, vancomycin
and oxacillin MICs were determined by Etests (AB Biodisk,
Solna, Sweden), as recommended by the manufacturer, and
were interpreted according to established CLSI breakpoint
criteria [8]. Methicillin resistance was determined by oxacillin
and cefoxitin disk-diffusion methods, and was confirmed by
determining the oxacillin MIC [9,10]. S. aureus ATCC 29213
and ATCC 25923 were used as quality controls in each batch of
Etests and disk-diffusion tests, respectively. Linezolid, teicopl-
anin and vancomycin MICs were rounded to the next highest
standard MIC doubling dilution (i.e., 0.25–64 mg ⁄L) for use in
the simulations.
Antibiotics
Steady-state exposure was assessed for the following antibiotic
regimens using the methodology described below: linezolid
600 mg every 12 h; teicoplanin 400 mg (6 mg ⁄ kg) every 24 h;
teicoplanin 800 mg (12 mg ⁄kg) every 24 h; vancomycin
1000 mg every 12 h; and vancomycin 1000 mg every 8 h.
Pharmacokinetic ⁄pharmacodynamic model
Mean pharmacokinetic parameters and their distribution were
extrapolated from published patient studies for each antibiotic.
The pharmacokinetics of linezolid were derived from phar-
macokinetic analysis of a population of 318 infected adults
treated according to the linezolid compassionate use protocol
[11]. Since linezolid pharmacodynamics are predicted by the
total area under the curve to MIC ratio (AUC ⁄MIC), only total
body clearance was required (6.85 ± 3.45 L ⁄h). AUC0–24 was
calculated via the equation, Dose24 h ⁄Clearance = AUC0–24,
which was then divided by each MIC dilution between
0.25 mg ⁄L and 64 mg ⁄L to calculate AUC ⁄MIC.
Teicoplanin population pharmacokinetics were derived
from a population of 30 febrile and severely neutropenic
patients with haematological malignancies [12]. Although
AUC ⁄MIC was utilised as the pharmacodynamic parameter
to predict teicoplanin efficacy, concentration–time profiles
were simulated for multiple dose regimens (i.e., every 12 h
loading dose for three doses) until steady state was reached
using a two-compartment open model. This was to account for
the unique loading dose of teicoplanin, as well as its long half-
life. As a result, total body clearance (1.15 ± 0.56 L ⁄h), volume
of the central compartment (6.56 ± 4.01 L), k12 (1.29 ± 0.62 h
)1)
and k21 (0.18 ± 0.075 h
)1) were all required to calculate
exposure. AUC0–24 was then calculated using the trapezoidal
rule after five simulated days of teicoplanin dosing. AUC0–24
was divided by the MIC at each doubling dilution to calculate
AUC ⁄MIC.
The pharmacokinetics of vancomycin are highly associated
with the creatinine clearance (CrCl) of the patient. As a result,
a linear equation developed from analyses of 37 adult patients
with various degrees of renal function, and validated in 30
patients with pneumonia [13,14], was used to estimate total
body clearance based on CrCl (mL ⁄min), whereby clearance
(L ⁄h) = [(CrCl · 0.79) + 15.4] · 0.06. CrCl was simulated as a
range between 50 mL ⁄min and 120 mL ⁄min, i.e., at a level
where most clinicians would not yet consider dose modifica-
tion because of renal dysfunction. The resulting mean vanco-
mycin clearance was 4.94 ± 0.68 L ⁄h.
The AUC0–24 and AUC ⁄MIC were calculated as described
above for linezolid. An additional analysis was performed
using free drug exposure for vancomycin; protein binding of
30% was assumed.
Monte-Carlo simulation
A 5000-patient Monte-Carlo simulation (Crystal Ball 2000;
Decisioneering Inc., Denver, CO, USA) was performed to
calculate a population of total AUC ⁄MIC exposures for each
antibiotic regimen at each MIC dilution. Clearance, volume of
the central compartment, k12 and k21 were each assumed to
follow log-Gaussian distributions during simulations. For the
vancomycin simulation, CrCl was assumed to follow a
triangular distribution, with a minimum value of 50 mL ⁄min,
a maximum value of 120 mL ⁄min, and a most likely value of
85 mL ⁄min. This assumption provided the best estimate of
vancomycin clearance in a patient population with normal
renal function. The number of simulated patients achieving the
target pharmacodynamic exposure at each MIC was counted
and reported as a percentage of the total population (i.e.,
probability of target attainment at that MIC). Targeted phar-
macodynamic exposures included a total AUC ⁄MIC >82.9 for
linezolid and a total AUC ⁄MIC >345 for vancomycin [15,16].
The linezolid pharmacodynamic target was identified using a
neutropenic murine thigh infection model. The vancomycin
target was identified in patients with pulmonary infections.
Additionally, a free drug AUC ⁄MIC >180 for vancomycin was
analysed, which was the exposure required for a bacteriostatic
response in a neutropenic murine thigh infection model [17].
Since established pharmacodynamic targets were not available
for teicoplanin, the vancomycin total drug AUC ⁄MIC target
was employed. Cumulative fraction of response (CFR) for the
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requisite pharmacodynamic target was calculated by weight-
ing the probability of target attainment at each MIC by the
percentage of organisms with that MIC, as previously
described by Drusano et al. [18]. For analyses, the staphylo-
cocci were divided into six groups: (i) all S. aureus; (ii)
methicillin-susceptible S. aureus (MSSA); (iii) MRSA; (iv) all
CNS; (v) methicillin-susceptible CNS; and (vi) methicillin-
resistant CNS.
A sensitivity analysis was conducted to explore the robust-
ness of the CFR results against the S. aureus populations.
Pharmacodynamic targets (i.e., AUC ⁄MIC) ± 15% for vanco-
mycin and teicoplanin were varied to determine the effect on
CFR. Overall, 70% of the patients in the vancomycin pharma-
codynamic study had predicted AUC ⁄MIC values within 15%
of the actual AUC ⁄MIC when the above clearance equation
was applied [14]. This is synonymous with requiring a total
AUC ⁄MIC of >293 or >397 and a free AUC ⁄MIC of >153 or
>207. Total AUC ⁄MICs of >38.9 and >167 were also explored
for linezolid, as these values were the low and high requisite
exposures reported in the initial in-vivo pharmacodynamic
experiments [15]. Finally, a teicoplanin trough value of
>10 mg ⁄L was investigated, since this target has been reported
previously to be predictive of clinical success for the majority
of serious infections [19,20]. However, it should be noted that
trough concentrations alone are not entirely appropriate
pharmacodynamic targets, as they are not linked to the MIC
for a particular organism.
RESULTS
In total, 119 S. aureus isolates were included in the
analysis, among which 40 (33.6%) were consid-
ered to be MRSA according to disk-diffusion, with
the majority having oxacillin MICs >256 mg ⁄L.
Among the S. aureus isolates, 105 were from
blood ⁄ catheter samples, and the remainder were
from quantitative bronchoalveolar lavage (n = 9),
urine (n = 3) and tracheal aspirate (n = 2) cul-
tures. There were 82 CNS isolates included in the
analysis; 74 (90.2%) were considered to be meth-
icillin-resistant according to disk-diffusion, with
oxacillin MICs >4 mg ⁄L for the majority of the
isolates. All CNS were isolated from blood in at
least two consecutive cultures (only one isolate
was included in the study). Table 1 summarises
the MIC distributions of linezolid, teicoplanin
and vancomycin for these organisms, grouped as
all isolates, methicillin-susceptible isolates and
methicillin-resistant isolates.
The resulting total drug AUC exposures simu-
lated for each regimen are summarised in Table 2.
The probability of target attainment for each
antibiotic regimen analysed is presented in
Figs 1–3. Linezolid, teicoplanin 800 mg and all
vancomycin regimens achieved >90% target
attainment up to MICs of 1 mg ⁄L. Above this
Table 1. MIC distributions for staphylococcal isolates
included in the study
Bacterial group (n)
and antibiotic
Percentage of bacteria at each MIC value (mg ⁄L)
0.25 0.5 1 2 4 8 16 32 64
All Staphylococcus aureus (119)
Linezolid 1.7 29.4 66.4 1.7 0.8 0 0 0 0
Teicoplanin 0.8 2.5 49.6 42.9 4.2 0 0 0 0
Vancomycin 0 0 53.8 45.4 0.8 0 0 0 0
MSSA (79)
Linezolid 2.5 22.8 73.4 1.3 0 0 0 0 0
Teicoplanin 1.3 2.5 68.4 26.6 1.3 0 0 0 0
Vancomycin 0 0 67.1 32.9 0 0 0 0 0
MRSA (40)
Linezolid 0 42.5 52.5 2.5 2.5 0 0 0 0
Teicoplanin 0 5.0 12.5 72.5 10.0 0 0 0 0
Vancomycin 0 0 27.5 70.0 2.5 0 0 0 0
CNS (82)
Linezolid 0 64.6 32.9 2.4 0 0 0 0 0
Teicoplanin 0 6.1 12.2 31.7 23.2 13.4 6.1 3.7 3.7
Vancomycin 0 0 12.2 76.8 11.0 0 0 0 0
MS-CNS (8)
Linezolid 0 75.0 12.5 12.5 0 0 0 0 0
Teicoplanin 0 0 62.5 0 12.5 25.0 0 0 0
Vancomycin 0 0 25.0 75.0 0 0 0 0 0
MR-CNS (74)
Linezolid 0 63.5 35.1 1.4 0 0 0 0 0
Teicoplanin 0 6.8 8.1 35.1 23.0 12.2 6.8 4.1 4.1
Vancomycin 0 0 10.8 77.0 12.2 0 0 0 0
MSSA, methicillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus; CNS,
coagulase-negative staphylococci; MS-CNS, methicillin-susceptible coagulase-neg-
ative staphylococci; MR-CNS, methicillin-resistant coagulase-negative staphylo-
cocci.
Table 2. Mean and standard deviation of 24-h total drug
area under the curve (AUC) resulting from Monte-Carlo
simulations
Antibiotic Dosage
24-h total AUC
(mg*h ⁄L) (mean ± SD)
Linezolid 600 mg every 12 h 220.2 ± 115.4
Teicoplanin 400 mg (6 mg ⁄ kg) every 24 h 373.3 ± 164.3
800 mg (12 mg ⁄ kg) every 24 h 745.6 ± 328.6
Vancomycin 1000 mg every 12 h 420.2 ± 60.6
1000 mg every 8 h 630.4 ± 90.9
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Fig. 1. Probability of linezolid 600 mg every 12 h achiev-
ing a total AUC ⁄MIC >82.9 at increasing MIC dilutions.
118 Clinical Microbiology and Infection, Volume 14 Number 2, February 2008
 2007 The Authors
Journal Compilation  2007 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 116–123
MIC, target attainments declined for all agents,
with the exception of vancomycin 1000 mg every
8 h using the free drug target (i.e., fAUC ⁄MIC
>180), which was still able to achieve 90% target
attainment at an MIC of 2 mg ⁄L. Teicoplanin
400 mg achieved >90% target attainment only up
to an MIC of 0.5 mg ⁄L. The CFRs against the
S. aureus and CNS populations are summarised in
Table 3. Linezolid achieved the greatest CFR
against all S. aureus isolates and all CNS, followed
by vancomycin 1000 mg every 8 h (using the free
drug target) and teicoplanin 800 mg. The lower
doses of each regimen achieved appreciably
lower target attainment. A similar rank order
was maintained for the methicillin-susceptible
populations. Free drug CFRs for the lower vanco-
mycin dose did not differ appreciably from total
drug CFRs for any subdivision of the organisms.
Against methicillin-resistant CNS, only linezolid
achieved >90% CFR, while both linezolid and
vancomycin 1000 mg every 8 h (only using the
free drug target) achieved >90% CFR against
MRSA isolates. Considerable decreases in the CFR
were observed for the teicoplanin and all other
vancomycin regimens against MRSA.
Fig. 4 shows sensitivity analyses for both MSSA
and MRSA. At a requisite AUC ⁄MIC of 167 for
linezolid, the CFR declined to 70.9% and 74.2%
against MSSA and MRSA, respectively. The range
of CFRs tested for each antibiotic did not alter the
overall conclusion that linezolid would have a
higher likelihood of achieving pharmacodynamic
exposure. However, it was notable that exposures
against the methicillin-susceptible population
were much greater for the high-dose teicoplanin
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Fig. 2. Probability of teicoplanin achieving a total AUC ⁄
MIC >345 at increasing MIC dilutions with: (a) 400 mg
every 24 h; (b) 800 mg every 24 h.
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Fig. 3. Probability of vancomycin achieving a total AUC ⁄
MIC >345 or a free AUC ⁄MIC >180 at increasing MIC
dilutions with: (a) 1000 mg every 12 h; (b) 1000 mg every
8 h. Total drug probability of target attainment (PTA) is
represented by closed circles, and free drug PTA by open
circles.
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and vancomycin regimens. Additionally, vanco-
mycin 1000 mg every 8 h produced favourable
results against the MSSA population when analy-
sed using a free drug pharmacodynamic target,
and also performed admirably against MRSA,
with a lower limit of 71.6% CFR, which was
similar to that for linezolid. The same vancomycin
regimen, using the total drug pharmacodynamic
target, attained a very wide range of CFRs against
MRSA (30–74%). Sensitivity analyses for the CNS
revealed results similar to those observed with the
MRSA population (data not shown). Finally, the
teicoplanin 400-mg and 800-mg regimens
achieved a steady-state trough level of
>10 mg ⁄L in 46.3% and 83.0% of the population,
respectively.
DISCUSSION
This pharmacodynamic comparison of linezolid,
vancomycin and teicoplanin against clinically
relevant isolates of staphylococci from Brazil
revealed some interesting findings. First, the data
suggest that, overall, linezolid should have the
highest probability of attaining its requisite phar-
macodynamic target against staphylococci and,
moreover, methicillin susceptibility had no affect
on target attainment for this antibiotic. Second,
standard vancomycin (1000 mg every 12 h) and
teicoplanin (400 mg every 24 h) regimens
achieved a poor CFR against these clinical isolates
from Brazil. Higher doses of teicoplanin provided
reasonable target attainment against MSSA, but
not against MRSA. Finally, the performance of the
high-dose vancomycin regimen (1000 mg every
8 h) was highly sensitive to the pharmacody-
namic target utilised. Against a target derived
from patients with pneumonia, this regimen
would probably be insufficient. However, using
a free drug target derived from a murine thigh
infection model, high-dose vancomycin should
still be effective against these MRSA isolates.
The explanation of the differences in CFR
among regimens is rooted in the analysis of
Table 3. Cumulative fraction of
response (%) for Staphylococcus aur-
eus and coagulase-negative staphy-
lococci with different antibiotic
regimens
Organism and antibiotic regimen
All
isolates
Methicillin-susceptible
isolates
Methicillin-resistant
isolates
Staphylococcus aureus n = 119 n = 79 n = 40
Linezolid 600 mg every 12 h 96.0 96.6 94.8
Teicoplanin 400 mg (6 mg ⁄ kg) every 24 h 30.1 39.1 5.8
Teicoplanin 800 mg (12 mg ⁄ kg) every 24 h 71.6 81.4 21.4
Vancomycin 1000 mg every 12 h (total drug target) 48.0 59.9 24.6
Vancomycin 1000 mg every 8 h (total drug target) 65.1 75.3 44.9
Vancomycin 1000 mg every 12 h (free drug target) 57.4 69.7 33.1
Vancomycin 1000 mg every 8 h (free drug target) 94.6 96.7 90.5
Coagulase-negative staphylococci n = 82 n = 8 n = 74
Linezolid 600 mg every 12 h 97.8 94.9 98.1
Teicoplanin 400 mg (6 mg ⁄ kg) every 24 h 13.4 31.3 12.1
Teicoplanin 800 mg (12 mg ⁄ kg) every 24 h 34.6 59.4 33.1
Vancomycin 1000 mg every 12 h (total drug target) 10.9 22.3 9.7
Vancomycin 1000 mg every 8 h (total drug target) 31.3 43.7 30.0
Vancomycin 1000 mg every 12 h (free drug target) 18.3 31.0 17.0
Vancomycin 1000 mg every 8 h (free drug target) 81.3 92.5 80.1
Cumulative fraction of response (%)
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Teicoplanin 800 mg q24h
Vanco 1000 mg q12h (Total)
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Vanco 1000 mg q12h (Free)
Vanco 1000 mg q8h (Free)
Fig. 4. Sensitivity analysis for
cumulative fraction of responses
(CFR) against methicillin-suscepti-
ble and -resistant Staphylococcus
aureus populations. For each antibi-
otic regimen, results for methicillin-
susceptible isolates are shown in
open boxes, and those for methicil-
lin-resistant isolates in shaded
boxes. Each box represents the range
of CFR attained at the highest and
lowest pharmacodynamic targets.
The asterisk represents the CFR at
the initial pharmacodynamic target.
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probability of target attainment at each MIC
(Figs 1–3). Linezolid had a high probability of
achieving its requisite pharmacodynamic expo-
sure up to MICs of 1 mg ⁄L. Moreover, <5% of
these isolates had linezolid MICs >1 mg ⁄L. While
higher-dose teicoplanin and vancomycin (includ-
ing the free drug analysis) regimens were also
able to achieve their pharmacodynamic targets up
to 1 mg ⁄L, a substantially greater percentage of
these staphylococci displayed MICs of ‡2 mg ⁄L.
Only the free drug analysis of vancomycin
1000 mg every 8 h was able to achieve 90% target
attainment at an MIC of 2 mg ⁄L. In this study,
c. 46% of S. aureus isolates and 88% of CNS
displayed vancomycin MICs ‡2 mg ⁄L. This was
particularly common among the MRSA isolates.
Similar observations were found with teicoplanin.
As a result, simply increasing the dose to 800 mg
every 24 h for teicoplanin and to 1000 mg every
8 h for vancomycin when treating MRSA and
methicillin-resistant CNS infections still might not
provide sufficient pharmacodynamic exposure.
These results are supported by previous studies
which have concluded that vancomycin might be
less effective against staphylococci with MICs
‡2 mg ⁄L in serious infections [6].
Interestingly, the present data suggest that
higher doses of teicoplanin and vancomycin
may be suitable for methicillin-susceptible iso-
lates because the majority of these isolates have
MICs £1 mg ⁄L. The difference in glycopeptide
MIC distributions between methicillin-susceptible
and -resistant populations in this analysis con-
flicts with previous dogma that methicillin resis-
tance does not affect glycopeptide MICs.
Nevertheless, there are no data concerning the
use of these high doses against methicillin-sus-
ceptible organisms because most clinicians would
prefer to use a semi-synthetic penicillin or a
cephalosporin. Furthermore, standard glycopep-
tide doses have been demonstrated to be inferior
to b-lactams for the treatment of serious infections
with methicillin-susceptible staphylococci [21].
The limitations of this analysis include the
pharmacodynamic targets chosen. Unlike b-lac-
tams and fluoroquinolones, the pharmacodynam-
ics of these anti-Gram-positive antibiotics,
particularly the glycopeptides, are not well-eluci-
dated. Previous studies have suggested that the
effectiveness of these compounds is linked to time
above the MIC, whereas it is now considered that
AUC ⁄MIC values are better suited to predicting
bacterial response [17,22]. The targets used for
linezolid in the present study are supported by
findings from an in-vivo murine thigh infection
model, which is the reference standard for delin-
eating pharmacodynamic parameters and quan-
titative level of exposure [15]. To the best of our
knowledge, a pneumonia infection model for
linezolid has not yet been developed. However,
a retrospective analysis of the linezolid compas-
sionate use programme (which included extre-
mely debilitated patients treated for extended
periods for varying infections caused by a num-
ber of Gram-positive organisms) concluded that
higher success rates might occur at total drug
AUC ⁄MIC values of 80–120 for bacteraemia,
lower respiratory tract infections and skin ⁄ skin-
structure infections [23]. These values resembled
the targets identified in the murine thigh infection
model. Furthermore, at the highest pharmacody-
namic target reported (total AUC ⁄MIC ratio
>167), the linezolid CFR was 70.9% and 74.2%
for MSSA and MRSA populations, respectively
(Fig. 4). While these values are significantly lower
than the CFR at the average AUC ⁄MIC target of
82.9, they are still above the achievable total drug
CFRs for teicoplanin and vancomycin doses
tested in this simulation, particularly against the
MRSA population, suggesting that the pharma-
codynamic order of these drugs should remain
consistent. Although the present study utilised
total AUC ⁄MIC for linezolid, free drug exposures
did not predict efficacy any better in the original
pharmacodynamic studies, and would be cor-
rected for protein binding in both the numerator
and the target, thereby resulting in no change in
the CFR.
A similar model for vancomycin has not been
published, although data presented almost two
decades ago suggested that a free drug AUC ⁄MIC
of c. 180 was required for a bacteriostatic response
in a neutropenic murine thigh infection model
[17]. Vancomycin was analysed using both the
free drug target of 180 and a total AUC ⁄MIC
target (>345) from more recent patient studies
involving pneumonia [14,16]. With a protein-
binding correction factor of c. 30% for vancomy-
cin, the pneumonia target would have been 240, a
value greater than the bacteriostatic exposure
from the murine thigh infection model, suggest-
ing that this requisite exposure might only apply
to pulmonary infections and not to other types of
infections. As a result, for pulmonary infections
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caused by MRSA, even increasing the dose of
vancomycin to 1000 mg every 8 h would not
predict improved outcomes, because target attain-
ment is low at MICs of 2 mg ⁄L. However, for
other infections, where the free drug bacteriostatic
target of 180 might apply (e.g., complicated skin
and skin-structure infections), this dose of vanco-
mycin should perform well, even for isolates with
MICs up to and including 2 mg ⁄L. Clearly, the
low dose was not able to achieve a good CFR
against MRSA, but the wide range of CFRs
observed for the higher dose brings into question
its reliability against MRSA for pneumonia and
other more serious infections, as suggested by
some clinical studies [17,24]. Applying the model
to hypothetical vancomycin regimens for pneu-
monia of 2000 mg every 12 h and every 8 h
would achieve 90% and 98.1% CFR, respectively,
against the MRSA isolates included in the present
study. These regimens would also achieve 89%
and 100% probability of target attainment, respec-
tively, at MIC values of 2 mg ⁄L. Unfortunately,
clinical experience with such high doses is limited
and their use would probably not be advocated
because of toxicity concerns.
Regrettably, no AUC ⁄MIC targets were avail-
able for teicoplanin; therefore, total drug vanco-
mycin targets were used, as both antibiotics are
glycopeptides, and targets within antibiotic clas-
ses tend to be similar. This is a broad generalisa-
tion, as some previous animal studies using the
murine peritonitis model have suggested that the
pharmacodynamics of the two antibiotics may be
different [25,26]. However, these studies also
found that both the maximum concentration to
MIC ratio (Cmax ⁄MIC) and time above the MIC
(T > MIC) were better predictors of reductions in
bacterial viable count than the AUC ⁄MIC, a
conclusion that seems illogical, since the AUC is
the product of both concentration and time. Free
drug exposures for teicoplanin were analysed
during the simulation (using 10% as the free
fraction and a reduced AUC ⁄MIC target based on
the vancomycin free drug target), and these
indicated 0% target attainment down to MICs of
0.25 mg ⁄L, which does not seem to agree with
clinical experience (data not shown). Rather,
teicoplanin is monitored more commonly by
assessment of trough values >10 mg ⁄L [19]. When
this MIC non-specific target was used, the results
for both doses were somewhat in agreement
with the AUC ⁄MIC results at an MIC of
1 mg ⁄L. A dose of 400 mg every 24 h achieved a
trough value >10 mg ⁄L in 46.3% of the popula-
tion. This was similar to the c. 50% likelihood of a
total AUC ⁄MIC ratio >345 at an MIC of 1 mg ⁄L.
Similarly, the 800-mg dose achieved the target
trough and AUC ⁄MIC ratios in 83% and 94% of
the population, respectively. However, it is diffi-
cult to interpret this agreement, since the majority
of organisms from earlier teicoplanin studies had
MICs of <1 mg ⁄L. Further studies are required
to confirm these pharmacodynamic targets
for vancomycin and teicoplanin when treating
staphylococcal infections.
In summary, linezolid had a greater likelihood
of obtaining its requisite pharmacodynamic expo-
sure against these S. aureus and CNS isolates from
Brazilian hospitals, and was unaffected by meth-
icillin resistance. In contrast, conventional regi-
mens of teicoplanin and vancomycin performed
poorly against isolates with MICs of >0.5 and
1 mg ⁄L, respectively, which was characteristic of
the majority of methicillin-resistant bacteria in this
population. Higher doses improved the CFR for
both glycopeptides, notably against methicillin-
susceptible bacteria, but because of the high
frequency of bacteria with MICs ‡2 mg ⁄L, consid-
eration should be given to the use of alternative
agents for treating serious staphylococcal infec-
tions in these hospitals.
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